You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Covid-19: Feluda test roll-out in a few weeks, says Harsh Vardhan

Emergency use of Covid-19 vaccines only after trial data

Coronavirus | Coronavirus Vaccine | Coronavirus Tests

Ruchika Chitravanshi  |  New Delhi 

Harsh Vardhan
File Photo of Health Minister Dr Harsh Vardhan

The Feluda paper strip test for Covid-19 diagnosis will be made available in the next few weeks, Health Minister said on Sunday.

The test, developed by Tata group and the Council of Scientific and Industrial Research (CSIR) using the gene editing technology, has been approved by the Drug Controller General of India (DCGI) for a commercial launch.

Private lab tests and trials on more than 2,000 patients at the Institute of Genomics and Integrative Biology have shown higher accuracy in Feluda test, compared to the RT-PCR one, the health ministry statement said.

The minister, while addressing a weekly social media dialogue, warned of increased transmission of during the winter season.

He said the government was deliberating the emergency use authorisation of Covid vaccines in India. “Adequate safety and efficacy data is required for emergency use authorisation vaccine approval for ensuring safety of patients. Further course of action will depend on the data generated,” he said.

Very few countries, including China and the UAE, have allowed such emergency authorisation for Covid vaccine. Russia has a temporary registration of its vaccine Sputnik V till January 2021 subject to Phase III trial. If a regulator sees a reasonable likelihood of a drug or vaccine being useful and lives of people under threat if it was not used, it can allow its use for public health emergencies.

The government is planning to roll out the Covid-19 vaccine by prioritising target groups and that the initial supply is expected to be limited, Vardhan said while addressing a weekly social-media dialogue.

He said the prioritisation of groups for Covid-19 vaccine would be based on two key considerations —occupational hazard and risk of exposure to infection, and the risk of developing severe disease and increased mortality. “India is looking at the availability of several different types of vaccines, of which some may be suitable for a particular age group while others may not be.”

Among the three front-runners for Covid vaccine in India, the vaccine by Serum Institute of India and Bharat Biotech requires two doses while the Cadila Healthcare vaccine requires three doses. The government is open to assessing the feasibility of introducing several Covid-19 vaccines in the country as per their availability for the Indian population, Vardhan said.

With the upcoming festive season raising concerns of a wider spread of the disease, the health minister said, “No religion or God says that you have to celebrate in an ostentatious way, that you have to visit pandals and temples and mosques to pray.”

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, October 12 2020. 00:59 IST